The Conversation (0)
Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) ("Sixth Wave", "SIXW" or the "Company") is pleased to provide an update on the Company's growing patent portfolio. The company has signed a Letter of Intent (LOI) and Assignment Agreement with Sara Magdouli, Ph.D. and Ali Entezari-Zarandi, Ph.D. The parties will collaborate on the development of "green lixiviants" as an alternative to conventional chemical reagents for recovery of Gold (Au), Lithium (Li), Rare Earth Elements (REE), and other metals. A lixiviant is a liquid medium used in hydrometallurgy to selectively extract the desired metal from the ore or mineral. It assists in rapid and complete leaching, for example during in situ leaching. The metal can be recovered from it in a concentrated form after leaching. The patent will be solely in the name of Sixth Wave and the company will have exclusive ownership of the IP, subject to a reasonably agreed-upon license fee to the co-inventors.
This work has led to the development of various novel reagent formulations capable of dissolving gold from concentrates with promising results in terms of its potential use for treatment of hard-to-leach or refractory golds. "We are highly motivated to pursue our collaborative efforts regarding green research and development opportunities," states Sherman McGill, Executive Vice-President of Sixth Wave, Inc. "Adding this technology to the Company's line of IXOS® nanotech extraction polymers used for gold mining will greatly broaden the company's innovative portfolio of products available to the global mining industry. Mining companies are aggressively looking for "green lixiviants" that use innovative, cutting-edge technology to mine metals that have explosive global demand such as Lithium, Cobalt, and REEs."
Green lixiviants garner attention due to their unique properties which are mostly non-toxic and biodegradable with negligible or no vapor. Environmental and social responsibility are vitally important components of Sixth Wave's corporate culture and are increasingly mandated by governmental regulation. Therefore, increased research devoted to metal recovery using environmentally friendly lixiviants for high-value targets such as Li, Co, (REEs) from spent magnets, and rare earth carbonate mineral, as well as zinc and lead removal from electric arc furnace dusts should prove very profitable to the company.
About Sixth Wave
Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system and IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.
Sixth Wave can design, develop, and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.
For more information about Sixth Wave, please visit our website at: www.sixthwave.com
ON BEHALF OF THE BOARD OF DIRECTORS
"Jonathan Gluckman"
Jonathan Gluckman, Ph.D., President & CEO
For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com
Cautionary Notes
This press release includes certain statements that may be deemed "forward-looking statements" including statements regarding the planned use of proceeds and performance of the AMIPs™ technologies. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the AMIPs™ technology are subject to the risk that the AMIPs™ technology may not prove to be successful in detecting virus targets effectively or at all, the uncertainty of medical product development, the uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the patent is not granted. The Company has not yet completed the development of a prototype for the product that is subject of its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100932
Figure one: Individual patient (001-005) and pooled results highlighting improvements in fibromyalgia domains as presented by University of Michigan 9 August 2024 (adapted)
Figure two: Individual patient and pooled results as presented by University of Michigan 9 August 2024 (adapted)